232 related articles for article (PubMed ID: 37322482)
1. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.
Kurnellas M; Mitra A; Schwabe T; Paul R; Arrant AE; Roberson ED; Ward M; Yeh F; Long H; Rosenthal A
J Transl Med; 2023 Jun; 21(1):387. PubMed ID: 37322482
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia.
Ward M; Carter LP; Huang JY; Maslyar D; Budda B; Paul R; Rosenthal A
Alzheimers Dement (N Y); 2024; 10(1):e12452. PubMed ID: 38356474
[TBL] [Abstract][Full Text] [Related]
3. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations.
Huang M; Modeste E; Dammer E; Merino P; Taylor G; Duong DM; Deng Q; Holler CJ; Gearing M; Dickson D; Seyfried NT; Kukar T
Acta Neuropathol Commun; 2020 Oct; 8(1):163. PubMed ID: 33028409
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by
Holler CJ; Taylor G; Deng Q; Kukar T
eNeuro; 2017; 4(4):. PubMed ID: 28828399
[TBL] [Abstract][Full Text] [Related]
5. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia.
Holler CJ; Taylor G; McEachin ZT; Deng Q; Watkins WJ; Hudson K; Easley CA; Hu WT; Hales CM; Rossoll W; Bassell GJ; Kukar T
Mol Neurodegener; 2016 Jun; 11(1):46. PubMed ID: 27341800
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors.
Swift IJ; Rademakers R; Finch N; Baker M; Ghidoni R; Benussi L; Binetti G; Rossi G; Synofzik M; Wilke C; Mengel D; Graff C; Takada LT; Sánchez-Valle R; Antonell A; Galimberti D; Fenoglio C; Serpente M; Arcaro M; Schreiber S; Vielhaber S; Arndt P; Santana I; Almeida MR; Moreno F; Barandiaran M; Gabilondo A; Stubert J; Gómez-Tortosa E; Agüero P; Sainz MJ; Gohda T; Murakoshi M; Kamei N; Kittel-Schneider S; Reif A; Weigl J; Jian J; Liu C; Serrero G; Greither T; Theil G; Lohmann E; Gazzina S; Bagnoli S; Coppola G; Bruni A; Quante M; Kiess W; Hiemisch A; Jurkutat A; Block MS; Carlson AM; Bråthen G; Sando SB; Grøntvedt GR; Lauridsen C; Heslegrave A; Heller C; Abel E; Gómez-Núñez A; Puey R; Arighi A; Rotondo E; Jiskoot LC; Meeter LHH; Durães J; Lima M; Tábuas-Pereira M; Lemos J; Boeve B; Petersen RC; Dickson DW; Graff-Radford NR; LeBer I; Sellami L; Lamari F; Clot F; Borroni B; Cantoni V; Rivolta J; Lleó A; Fortea J; Alcolea D; Illán-Gala I; Andres-Cerezo L; Van Damme P; Clarimon J; Steinacker P; Feneberg E; Otto M; van der Ende EL; van Swieten JC; Seelaar H; Zetterberg H; Sogorb-Esteve A; Rohrer JD
Alzheimers Res Ther; 2024 Mar; 16(1):66. PubMed ID: 38539243
[TBL] [Abstract][Full Text] [Related]
7. Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.
Arrant AE; Onyilo VC; Unger DE; Roberson ED
J Neurosci; 2018 Feb; 38(9):2341-2358. PubMed ID: 29378861
[TBL] [Abstract][Full Text] [Related]
8. Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons.
Hasan S; Fernandopulle MS; Humble SW; Frankenfield AM; Li H; Prestil R; Johnson KR; Ryan BJ; Wade-Martins R; Ward ME; Hao L
Mol Neurodegener; 2023 Nov; 18(1):87. PubMed ID: 37974165
[TBL] [Abstract][Full Text] [Related]
9. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin.
Hu F; Padukkavidana T; Vægter CB; Brady OA; Zheng Y; Mackenzie IR; Feldman HH; Nykjaer A; Strittmatter SM
Neuron; 2010 Nov; 68(4):654-67. PubMed ID: 21092856
[TBL] [Abstract][Full Text] [Related]
10. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis.
Ward ME; Chen R; Huang HY; Ludwig C; Telpoukhovskaia M; Taubes A; Boudin H; Minami SS; Reichert M; Albrecht P; Gelfand JM; Cruz-Herranz A; Cordano C; Alavi MV; Leslie S; Seeley WW; Miller BL; Bigio E; Mesulam MM; Bogyo MS; Mackenzie IR; Staropoli JF; Cotman SL; Huang EJ; Gan L; Green AJ
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404863
[TBL] [Abstract][Full Text] [Related]
11. Progranulin as a therapeutic target for dementia.
Galimberti D; Fenoglio C; Scarpini E
Expert Opin Ther Targets; 2018 Jul; 22(7):579-585. PubMed ID: 29889573
[TBL] [Abstract][Full Text] [Related]
12. Progranulin as a therapeutic target in neurodegenerative diseases.
Rhinn H; Tatton N; McCaughey S; Kurnellas M; Rosenthal A
Trends Pharmacol Sci; 2022 Aug; 43(8):641-652. PubMed ID: 35039149
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia.
Simon MJ; Logan T; DeVos SL; Di Paolo G
Trends Cell Biol; 2023 Apr; 33(4):324-339. PubMed ID: 36244875
[TBL] [Abstract][Full Text] [Related]
14. Progranulin deficiency induces overactivation of WNT5A expression via TNF-α/NF-κB pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers.
Alquézar C; de la Encarnación A; Moreno F; López de Munain A; Martín-Requero Á
J Psychiatry Neurosci; 2016 Jun; 41(4):225-39. PubMed ID: 26624524
[TBL] [Abstract][Full Text] [Related]
15. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency.
Lee WC; Almeida S; Prudencio M; Caulfield TR; Zhang YJ; Tay WM; Bauer PO; Chew J; Sasaguri H; Jansen-West KR; Gendron TF; Stetler CT; Finch N; Mackenzie IR; Rademakers R; Gao FB; Petrucelli L
Hum Mol Genet; 2014 Mar; 23(6):1467-78. PubMed ID: 24163244
[TBL] [Abstract][Full Text] [Related]
16. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
Ljubenkov PA; Edwards L; Iaccarino L; La Joie R; Rojas JC; Koestler M; Harris B; Boeve BF; Borroni B; van Swieten JC; Grossman M; Pasquier F; Frisoni GB; Mummery CJ; Vandenberghe R; Le Ber I; Hannequin D; McGinnis SM; Auriacombe S; Onofrj M; Goodman IJ; Riordan HJ; Wisniewski G; Hesterman J; Marek K; Haynes BA; Patzke H; Koenig G; Hilt D; Moebius H; Boxer AL
JAMA Netw Open; 2021 Sep; 4(9):e2125584. PubMed ID: 34559230
[TBL] [Abstract][Full Text] [Related]
17. A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy.
Sassi C; Capozzo R; Gibbs R; Crews C; Zecca C; Arcuti S; Copetti M; Barulli MR; Brescia V; Singleton AB; Logroscino G
J Alzheimers Dis; 2016 May; 53(2):475-85. PubMed ID: 27258413
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.
Kashyap SN; Boyle NR; Roberson ED
Neurotherapeutics; 2023 Jan; 20(1):140-153. PubMed ID: 36781744
[TBL] [Abstract][Full Text] [Related]
19. Microglial lysosome dysfunction contributes to white matter pathology and TDP-43 proteinopathy in GRN-associated FTD.
Wu Y; Shao W; Todd TW; Tong J; Yue M; Koga S; Castanedes-Casey M; Librero AL; Lee CW; Mackenzie IR; Dickson DW; Zhang YJ; Petrucelli L; Prudencio M
Cell Rep; 2021 Aug; 36(8):109581. PubMed ID: 34433069
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia.
Rosenthal ZC; Fass DM; Payne NC; She A; Patnaik D; Hennig KM; Tesla R; Werthmann GC; Guhl C; Reis SA; Wang X; Chen Y; Placzek M; Williams NS; Hooker J; Herz J; Mazitschek R; Haggarty SJ
Sci Rep; 2024 Apr; 14(1):9064. PubMed ID: 38643236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
